PMID- 29290256
OWN - NLM
STAT- MEDLINE
DCOM- 20181217
LR  - 20181217
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 115
DP  - 2018 Jan
TI  - Uncommon mutations in epidermal growth factor receptor and response to first and 
      second generation tyrosine kinase inhibitors: A case series and literature 
      review.
PG  - 135-142
LID - S0169-5002(17)30599-8 [pii]
LID - 10.1016/j.lungcan.2017.12.002 [doi]
AB  - Epidermal growth factor receptor (EGFR) is the most common driver gene involved 
      in non small cell lung cancer (NSCLC) growth, being found in approximately 10-15% 
      of Caucasian and 40% of Asian patients. A wide variety of pathogenic mutations, 
      deletions, insertions and duplications have been described in EGFR exons 18-21. 
      The presence of the most common among them (e.g. exon 21 L851R and exon 19 
      deletions) is associated to response to first and second generation EGFR tyrosine 
      kinase inhibitors (TKIs), which have demonstrated clear superiority over 
      chemotherapy in terms of both progression free survival (PFS) and overall 
      survival (OS) in all treatment lines. However, scarcity of data exists in 
      literature about the response of rarer EGFR alterations to first and second 
      generation TKIs, most works consisting in sporadic case reports and small case 
      series. In this review we aim to discuss the available evidence about this topic, 
      in order to derive suggestions for clinical practice. Furthermore, we report 
      seven cases of patients with lung tumors harboring uncommon EGFR mutations, 
      treated in our Institution with first or second generation TKIs.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Galli, Giulia
AU  - Galli G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Corrao, Giulia
AU  - Corrao G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Imbimbo, Martina
AU  - Imbimbo M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Proto, Claudia
AU  - Proto C
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Signorelli, Diego
AU  - Signorelli D
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Ganzinelli, Monica
AU  - Ganzinelli M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Zilembo, Nicoletta
AU  - Zilembo N
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Vitali, Milena
AU  - Vitali M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy; Medical Oncology Department, University of 
      Milan, via Festa del Perdono 7, 20122, Milan, Italy.
FAU - Garassino, Marina Chiara
AU  - Garassino MC
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy.
FAU - Lo Russo, Giuseppe
AU  - Lo Russo G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, via 
      G. Venezian 1, 20133, Milan, Italy. Electronic address: 
      giuseppe.lorusso@istitutotumori.mi.it.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20171205
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Pharmacological/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics
MH  - ErbB Receptors/genetics
MH  - Ex-Smokers
MH  - Fatal Outcome
MH  - Female
MH  - Gene Duplication
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Protein Kinase Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - EGFR
OT  - Response
OT  - Tyrosine kinase inhibitor
OT  - Uncommon mutation
EDAT- 2018/01/02 06:00
MHDA- 2018/12/18 06:00
CRDT- 2018/01/02 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2017/11/27 00:00 [revised]
PHST- 2017/12/03 00:00 [accepted]
PHST- 2018/01/02 06:00 [entrez]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/12/18 06:00 [medline]
AID - S0169-5002(17)30599-8 [pii]
AID - 10.1016/j.lungcan.2017.12.002 [doi]
PST - ppublish
SO  - Lung Cancer. 2018 Jan;115:135-142. doi: 10.1016/j.lungcan.2017.12.002. Epub 2017 
      Dec 5.